Embed Size (px)
Citation preview
vilotvi
<r. ujaw
a:.
interest)n. ^fl^nn?M?-5^^Tunavi'5ia^jaa^^e-3>bJ^^l^ viaiauaviia^fjycyTin
i
te. ^^wu uac^aJMtJflTjiviiJiyiviiail^Iouiia^n^nniviiiJru iyiaila<5n\jSi^n^iwf^iJ^^la^^<u<^^D<^au (Conflict of
a-5fini?vi (Organization Governance) ^ai^mviii^uinil^^iJ^^ti
(Corruption Free) in^nm^lvfvi1ern^?<u3iitiii (Bribery)
(Corruption Perception Index : CPI)
(Integrity and Transparency Assessment : ITA )
a: U'1
mm mum
(MOPH Code of Conduct)
IUinw^im^lfMuviSi4 Uivnisn
\Ji^^t]w\J^w^u1^auiJnai^vi
^hm^i wailmaw tsmwnuwi ^a
vrn^iamiviaiw ( Zero Tolerance)"
vi.fi. kxbk>
1
^n Sunmia^Tuvi
1•#
a>nuvi
ifo^^smon
(Agenda Based)
•f •
•*•
en/iav^na^a ^jvnwaTae^ tvn. oa: ^aeio^ wo >oiooocnte.mo®/ ®s^d*i\m ®m JlyiWU
nW ^W
m.
^^^w^^
f|]i
: SP - RM - 001
••'••" ^VI
6.6
6.5
G,H,i
^ ^t^i^'i^M
1 mu
6.4
H
j
( Risk Management Committee : RMC)
*
6.3
=0
ioo%
100%
^80%Near Miss
^^ G -1
D - F (Moderate Risk)
u G - I (High Risk)
D -1 Mrufrnvn RCA ueu6.
7.
1.
2.
3.
Svahviuiviy6.9
^u- •n^Tu^^n^tu/ m-sunliidiyvn
(Risk p
D ^1 ^tJi^^^^funm RCA
H RCA ^u C
Specific Clinical Risk u^ Non Clinical Risk
Common Clinical Risk
vi1c^liI^ww*Tii (FIDlt^ (Risk profile)
(PUT)
?inliwvn\j Risk profit^ ^n
*ui|j\^^MnMn (Pa)
RCA
3
la-a , . .. . ^i^.^W^ ^.
t^^v Ivlmn^^if^ yfswfy/gf^^u ^^veiiS&m&mn
V <=t 1/m a
MB4inpi/mm8MWh
^^d^Wrumffnwi w
ifi^vunno vrid
•Unuran^fthttMfHioB^^^ni u^iddifiimffn^n
D
uw
uw
mmzvw
!^
B
8.1
FR - rm 006
(CQl / TQM)
(Action To Manage Risk) u^^sviu
HAwn viia^
^ (FR - RM 007)
9.6
9.5
Feedback vnhwnunoto 1E -I vm RMC
ivievin RCAivi RMC
RCA vwth^ms^nmjjn RMC
A tvfa^\)8i-^V|n'Tuvi 25'Tuvi
incident Report Qmja?^susn??ijm?ij1vmfmjJiatj
wis
lJ^^^
(Incident Re9.4
f,'it!'
8n
10.2 mw^vmrn-w^m {Risk Management / RM)
^i^ m^im\xuW mUMmwzm m
10.1
i nn
im3 nu
9.8
9.?
^^
'0
x
<
^
^a^wa ^a^
vi
/ ^viswO^a /
ua^^a^num^^^^a (IC)
Ithunw^l 3
sni^u^umi^^n^ (PCT)
vw rmvifiwv
11.1 fmu^u^A\) (Non Clinical Risk) vunv^^
\)^s?i^^Uiinin^je4mjmi9ju^in^N\)^a dn
11.2 frni^wvn^i3iin (Common Clinical) vivna^
^ho wviviivl wttJ^^<l5^fn^"vff8J4Mamwjls^^Qlo8^lTii)'njni
(Sentinel Events) wno^^10.6
10.5 ivw^m^wliii^\lia^ (Adverse Events)'
10.4
- *^-vsw10.3
r t
p*(CQITQM)
9.6 irn^fninw4tM ( Action To Manage Risk)
ha
9.5
3 ifSou
IiuiuiitIb^ji ( fr - rm 007)
RCA W rmc jnol
rmc strca
tu m® •Si
U Feedback• fmumjfmu^UU1*E-I
>i'nfmuitKN (
Report )
T^
II1
i3.
9.8
FR.-RMOH)
•
• mmwowu
fr - rm ooe
200,000
u.
(fhiri™™uiwufnv 55-60)ufn
\r\mr\i consult
Vllftl^^ / VIT Medication reconciliation mOff4MO^^Tn'i4 7VI.
2561 ^ij 7bin til no ^1^ 58 lJ HN 56855 (CAPD ) JJI^Ut^Vl^^I^^ BP 158/7^"1 .•*^• l^Q^ /*T
mlodipine-5 mg 2x1 pc ^llluuwi^tni^vi^Ul^^o 3/10/61 ( BP 158/72 ) Uffo^^ni
I^i^il^o^nn I^.^fi^u viu-ji 19/IO/6I BP143/94 mmHg 1
1114 lxl pc
irL^Wj/. .ji J^ij^V'l ^"-1
®Flo do % tli^nau^iaSmart Hospital
sio,ooo U1VI
To be number one iJi^u'iflii.^a'uqufnwus tedbm 1"usi
n^anal ^^a
todbented^^te - lo
HA
®. i^ 6il T^au^^aTUVl tem)
tl lod^ite (envnuhmma)uaul^
amna^
na/siwv)
ITAen.
®. ^ani.i'ufcu'ufi'u'u^jviniijjmiaanm^nia il^^
®.® I'w.'ui^iLviviejvn^u i^inu i^o.ooo unvi
©.is ^viniiwaauvif^^^nsn^wfj^aTias^ amTU <t:o,ooo unvi (inn.sfs.vv(®nv
^
^^n.cno - ^b.eno "U.
ii'ufcu'u
vu enm
TUV1m\J.
"unEJimYimJfnfto
LQ^1 6)0.00 TJ.
^u ?nu OPD
fli^^VI ob/lsdben
TUVI ai 5-UQIfm fodbk)
^i^anviun
un^wu^aauw ^iajei^via fuvi^^
te^ ma
t^a-3
"Ii-^^aiun^v^iau^ tiiviu^arniyjai^ (Zero,
Tolerance) u,a'^5^'3U'iJjf!mjJi'3Jj2a1ufni^ruiPi^au<Hjj^3ja^atii'5iJWUU,'U'u ^ a^^n^Si^unfiuigi w'nu
n^ln rn<3ilis^L2uf:iai5'3'5JJi,i,^tifsniuIiJ^l?(tunT5<nn-3iu \Ji^anil
itu laimnvHi^^anui^vm^u^ iviaL^lum'3aei^^3aan^-3mii^la^(iu(5ia'ffiJ'm^ naumiauiu
i?e^mTfla^nuwmhs1!a'WU'mjBau a^
ieiEJ-3 m ^n nu miil^^ wi^iuviana in^ w^<U'3 'la<i8'uiTuiau'luvi'U'3 a^nu
a a?^ maiuTuvl ism su^iphj tect^>te
©.HA iwiojj^muvi^aumif'uiJisi.S^ Reacradit fif-^vi is tuvi g^-sio su^i^iu
Tuvl
WVl
Smart Hospital
^vf enJ^VllJ^JJ - TU-5Q-5
syi is
ENV
i^uwtuvi !
io<bsn
u vrmwurniriaeim^a^ui tiui^^ ^o via^
1/
-tuv!
-tuyi
Yia^aau)r
- TUVHTU
•^f)f3iama<u
©o tu HiHana
amnavi^a^^ fin Hi =o
mm(ma) ?) k>bn l^^ia
- FCU-Ast
®.
rmp
ENV
PCT
PO
ME
IC
n^umi
niiunn
aiwu fflb ma
RMUilisBTUfmurm
dr.
via-alu
.u.a.ncyBui via-^lu
w^n
silo,
®o.'u.a.
via^u'a
!. •u.a.svn^^u aa^fl
b.
^k <UQJ
eia fl^n^vn
h.
en.
ihsanil^ibsjnw
/te^oteVI
w tuvi ©©
^® n^nfjiFUJ1 ft d^Lvi iai viui vi viV Vvi^ Lv
GIG).
via-au'a
b.
d.
^.
if •< s'sro^^'.W. i
(MOPH Zero Tolerance)
cs^w4iyy5vi5.vh1lijite<t:tote nai ®o,oa%i. w aiy OPD
fhtm^mlI^^eninfivrntijj^ ^y^ It^ oomb.acw/eiMT^Vi to
mmf^ua
^i ^^ S-^s,
1a aaanan
asan*sanna waivla^
vtm WO.OO-U.
nan o.mo u.
nan .oou
nan ®©.tno u.
u.nan
a^anatu an^OPD Ivianunavi^na\ja
nruvl g
fu^^oau ita
'Um9sii)utfnrmiJ494to.®
to.
uanannu 9
^ni in
©.en
Bswu€4Rnta"ufi4isjmj^4fiiii a^i
^ais pmmtlyfiai4iias^^ni4i^^8Biw2'uv!'unvi
tou wTun
CPl
iW.vi.) MiJ
"094
©.©
inmvht^^
/nvnwrw^...
vib
te,m m^^^^iMfl^^iiiaa4inainiJwai)'3Ias<wutBau viinaa^ n^syTufi^^ia^sM
to.) \Mamauan ^u a^viiJia isi^au
^ia^VT
nnnu^u.a'Uivna^
ah to ^^aaa
^.) m^flB^'ungisi^^auviiangmnBmnEn^^ ^a
kviinsau
m.) fmiua^rvuna^ ^a
te.)
^wjm
te.ie
anf) niiu^^i
m^n^ifTU
auwa
,)
®oo122
A^ao^j^
ua^
122
I'sa-^via^
^^vn'i-3
122
wa^JisIatnlwu
•^aw
V)2fimm^a^
inaifrurraiJU'ul^'iuvia'iBi^^a
1^2
kx^bm
122
fa^liau 13
tac^bto
b^^^® I^alUi2i?a^^e^ai1anna>nIvim^iviiJivi^e^^^-mo
vi^e^^^ ^w
vi e
b.
-m-
^8^im^w5nnviiwnjj^nfiTJ<D"Kiwu
wu
to.
• (to.)
of.)
mmuy^
m.)
to.)
IM1I8
. fm<U?stSj'U^^^^i^a4 (Risk Assessment)to
^4lvi'avn4B<ua^ia1ljJ^nai^4 /nRvf^u^ .
a4lvi'a¥n4^ija1.ii^nai^4 ^aiiui^au
a^'lvi^vn^Qijaiji^'iai^ aai^m^au
a^Ivi'wvn^Bija^naiii^ iJaaaan' -
a4^<M'vn4B'ua?nat^4 laaan
maB^naJV1V
Tamain^i^^uann . , ^lamain^uuuaa
^arn^in^t)'uiji4 . .. ..
lafii^inati'utiaaf^
tarnain^^itl^Jil^san /fl^asu^a
•uaainn
•uaa
ilntjnan^^^
fj^^n
^^u-ssaiufl'3ii^'uui4iia4Man'5;
^aa^nn
uaa
thumrwfj4fj4uin
TamsiYiatJi^^^)
©
to
en
or
<t
inwwnp
©
to
en
€.
<t
9^^ k
--
©.
